Related Experiment Video
Updated: Mar 27, 2026
12:58
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
9.5K
Novel therapies for severe Clostridium difficile colitis.
Paul Waltz1, Brian Zuckerbraun
1aDepartment of Surgery, University of Pittsburgh bDepartment of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Current Opinion in Critical Care
|January 16, 2016
Summary
Clostridium difficile infection (CDI) management is evolving. Future treatments may combine microbiome restoration and immunotherapies for improved cure rates and reduced recurrence of this common healthcare-associated infection.
Area of Science:
- Gastroenterology
- Infectious Diseases
- Microbiome Research
Background:
- Clostridium difficile infection (CDI) presents a significant healthcare challenge due to rising incidence, frequent recurrence, and substantial morbidity/mortality.
- CDI severity ranges widely, necessitating diverse therapeutic strategies.
- Current severe CDI treatments involve supportive care, agent discontinuation, and antibiotics.
Purpose of the Study:
- To review current management strategies for Clostridium difficile infection.
- To explore emerging therapeutic approaches for CDI.
- To discuss the future of CDI treatment, focusing on novel modalities.
Main Methods:
- Literature review of recent advancements in CDI treatment.
- Analysis of emerging therapies targeting the microbiome and host immune response.
- Evaluation of novel antibiotic and immunotherapy development.
- Assessment of alternative surgical interventions.
Main Results:
- The gut microbiome's role is increasingly recognized, offering potential for therapeutic interventions.
- New antibiotics and targeted immunotherapies are under development to neutralize C. difficile toxins.
- Less invasive surgical options are being explored as alternatives to subtotal colectomy.
Conclusions:
- Future CDI management will likely adopt a multimodal approach.
- Focus on microbiota restoration and immunotherapies promises enhanced efficacy and reduced recurrence.
- Further understanding of CDI pathogenesis is crucial for optimizing treatment outcomes.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
608
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
608
01:17Drugs for Treatment of Diarrhea-Predominant IBS
855
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
855
01:29Inflammatory Bowel Disease IV: Pharmacological Management
920
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
920
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
659
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
659
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
538
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
538
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
616
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
616